Current practice of radioiodine treatment in the management of differentiated thyroid cancer in Germany

Hoelzer, Simon; Steiner, Dagmar; Bauer, Richard; Reiners, Christoph; Farahati, Jamshid; Hundahl, Scott A.; Dudeck, Joachim
October 2000
European Journal of Nuclear Medicine;2000, Vol. 27 Issue 10, p1465
Academic Journal
Abstract. This prospective, observational study of a cohort of thyroid cancer patients in Germany focusses on the "real-world" practice in the management of thyroid cancer patients. This report includes data from 2376 patients with primary differentiated thyroid carcinoma first diagnosed in the year 1996. The study reveals considerable differences in actual practice concerning surgery and radioiodine treatment. The results indicate that consensus is lacking with respect to the multimodality treatment approach for differentiated thyroid carcinoma. Our analysis represents the most current and comprehensive national assessment of presenting patient characteristics, diagnostic tests, treatment and complications for thyroid cancer.


Related Articles

  • Reply. Sabri, O. // European Journal of Nuclear Medicine;2001, Vol. 28 Issue 3, p394 

    Replies to a comment made on an article about the treatment of differentiated nonmedullary thyroid carcinoma. Effect of thyroid uptake of a second application of radioiodine; Results of a reduction in thyroid uptake; Difficulty in quantifying how much of the administered radioiodine is absorbed...

  • Glitazone pretreatment boosted 1-131 uptake. Foster, Melissa // Endocrine Today;Dec2011, Vol. 9 Issue 12, p24 

    The article reports on a study which found that a short course of treatment with glitazone before radioiodine ablation enhances the uptake of radioactive iodine by cancer cells which could improve the treatment of metastatic differentiated thyroid cancer.

  • Evidence supports optional use of RAI for papillary thyroid cancer. Calabro, Anthony; Costa, Samantha; Foster, Melissa // Endocrine Today;Oct2012, Vol. 10 Issue 10, p16 

    The article reports that Iain J. Nixon, MBCHB, clinical fellow in the head and neck surgery department of Memorial Sloan-Kettering Cancer Center, has argued for the optional use of radioactive iodine for the management of papillary thyroid cancer.

  • Historical Note: TSH Suppression for Thyroid Cancer. Hurley, James R. // Thyroid;Nov2011, Vol. 21 Issue 11, p1175 

    The article discusses the suppression of thyroid-stimulating hormone (TSH) for thyroid cancer treatment. The author notes the rapid advances in thyroid disease diagnosis and treatment due to radioiodine availability in the 1940s. He presents some findings on TSH suppression as well as the...

  • Okay to stop radioiodine if it produces no significant effect. Kloos, Richard T.; Kalvaitis, Katie // Endocrine Today;8/10/2008, Vol. 6 Issue 14, p6 

    The article discusses the use of radioactive iodine as treatment for thyroid disease, according to R. Michael Tuttle, a member at Memorial Sloan Kettering Cancer Center. The general theory is to stop treatment when additional administered activities are unlikely to produce benefit. Clinical...

  • Brain Metastasis from Follicular Thyroid Carcinoma: Treatment with Sorafenib. Shen, Yan; Ruan, Maomei; Luo, Quanyong; Yu, Yongli; Lu, Hankui; Zhu, Ruisen; Chen, Libo // Thyroid;Aug2012, Vol. 22 Issue 8, p856 

    Background: Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma. However, its therapeutic effect has not been assessed in patients with brain metastases from follicular thyroid carcinoma (FTC). Here, we report a patient in whom this treatment...

  • The Effect of Ginkgo biloba Extract on Genotoxic Damage in Patients with Differentiated Thyroid Carcinoma Receiving Thyroid Remnant Ablation with Iodine-131. Dardano, Angela; Ballardin, Michela; Caraccio, Nadia; Boni, Giuseppe; Traino, Claudio; Mariani, Giuliano; Ferdeghini, Marco; Barale, Roberto; Monzani, Fabio // Thyroid; 

    Background: Radioiodine (131I) therapy is usually performed in patients with differentiated thyroid cancer (DTC). Although 131I is generally considered safe, genotoxic damage has been demonstrated both in vivo and in vitro. The aim of the current study was to evaluate the effect of Ginkgo biloba...

  • Radioiodine Treatment of Metastatic Thyroid Cancer: Relative Efficacy and Side Effect Profile of Preparation by Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin. Klubo-Gwiezdzinska, Joanna; Burman, Kenneth D.; Van Nostrand, Douglas; Mete, Mihriye; Jonklaas, Jacqueline; Wartofsky, Leonard // Thyroid; 

    Background: To effectively treat differentiated thyroid cancer (DTC) with radioiodine (RAI) it is necessary to raise serum thyrotropin (TSH) levels either endogenously by thyroid hormone withdrawal (THW) or exogenously by administration of recombinant human TSH (rhTSH). The aim of our study was...

  • Is Empirical Radioactive Iodine Therapy Still a Valid Approach to Patients with Thyroid Cancer and Elevated Thyroglobulin? Rosario, Pedro Weslley; MourĂ£o, Gabriela Franco; dos Santos, Juan Bernard Nascimento; Calsolari, Maria Regina // Thyroid;Mar2014, Vol. 24 Issue 3, p533 

    Background: At present, empirical radioactive iodine therapy is recommended for patients with thyroid cancer and elevated thyroglobulin (Tg) after initial therapy when neck ultrasonography (US), chest computed tomography (CT), and 18-fluorodeoxyglucose positron emission tomography (FDG-PET) do...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics